Novo Nordisk A/S has just reached another milestone in its meteoric rise: the market value of the Danish company has exceeded the size of its domestic economy.

The shares surged this week on news weight-loss drug Wegovy comes with a heart benefit. The gain catapulted the market capitalization above 2.87 trillion kroner ($423 billion), more than Denmark’s 2022 gross domestic product, and means Novo is vying for the title of Europe’s most valuable company.